GlassScriptPhysician profile
Ravinder S Sabherwal
NPI 1609840024
$4,388.33
in general payments reported to CMS, 2019-2025
22 companies · $578 in 2025
The $578 reported for 2025 was more than what 81% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,030 · 2020: $265 · 2021: $505 · 2022: $407 · 2023: $454 · 2024: $150 · 2025: $578.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,182.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,181.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,900.04 | 2019-2025 | Total30, Precision 1, Dailies Total1 |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $535.47 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $472.47 | 2022-2025 | Infuse, Biotrue One Day, Biotrue |
| Allergan, INC. | $339.47 | 2019-2022 | |
| Aerie Pharmaceuticals, INC. | $247.91 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $135.93 | 2019-2022 | |
| Abbvie INC. | $110.56 | 2022-2023 | Lumigan, Alphagan P, Vuity |
| Sight Sciences, INC. | $94.45 | 2025 | Tearcare System |
| Biotissue Holdings INC. | $84.53 | 2019-2025 | |
| Johnson & Johnson Surgical Vision, INC. | $70.05 | 2023-2024 | Tecnis Simplicity, Tecnis Iol |
| Shire North American Group INC | $62.28 | 2019 | |
| Novartis Pharmaceuticals Corporation | $61.20 | 2019-2022 | |
| Glaukos Corporation | $47.53 | 2024-2025 | Idosetr, Istent Trabecular Micro-Bypass System Model Is3 |
| Oyster Point Pharma, INC. | $42.94 | 2022-2023 | Tyrvaya |
| Thea Pharma INC. | $40.36 | 2024-2025 | Iyuzeh |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $29.51 | 2024 | Xdemvy |
| Amgen INC. | $27.95 | 2025 | Tepezza |
| Dompe US, INC. | $21.97 | 2021 | |
| Omeros Corporation | $20.23 | 2019 | |
| Abb Con-Cise Optical Group LLC | $19.45 | 2025 | Spectacle Lenses |
| Kala Pharmaceuticals, INC. | $12.52 | 2021 | |
| Ivantis, INC | $11.51 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ravinder Sabherwal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.